Matrix-backed Chinese biotech startup Genecast closes $43m Series D1 round

Genecast Biotechnology, a Chinese biotech startup that specialises in next-generation sequencing (NGS) technology and bioinformatics, has raised 300 million yuan ($43 million) in a Series D1 round of financing led by CICC Capital, an investment platform of China International Capital Corporation (CICC).